Foghorn Therapeutics
在场
Foghorn Therapeutics 的所有者是 Flagship Pioneering.
Flagship Pioneering 拥有 24家子公司，其中包括 Alltrna、Apriori Bio 和 Cellaritybio。
他们在：
高管
查看带有其 28 名主要高管的组织结构图
Foghorn Therapeutics 搜索最多的简介
- Adrian Gottschalk, Director, President and Chief Executive Officer
- Ian Smith, Director
- Thomas Lynch, Director
高管在Foghorn Therapeutics变化
- Anna Rivkin已作为Chief Business Officer加入公司 (新闻发布的2024九月3号).
- Kristian Humer已作为Chief Financial Officer加入公司 (新闻发布的2024四月17号).
高管在Flagship Pioneering变化
- Junaid Bajwa已作为Senior Partner, Head of United Kingdom and Science Partner, Pioneering Intelligence加入公司 (新闻发布的2024十月25号).
- Paul Parker已作为Managing Partner, Capital Solutions and Value Realization加入公司 (新闻发布的2024十月10号).
- Raj Panjabi已作为Senior Partner, Preemptive Health and Medicine Initiative加入公司 (新闻发布的2024八月7号).
创建提醒
跟踪 Foghorn Therapeutics 的高管变动
生物技术
Flagship Pioneering 拥有 2,333 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Visus Therapeutics and Tenpoint Therapeutics have merged (公布2024十二月27号)..
- Deerfield has announced the acquisition of Singular Genomics (公布2024十二月24号).
- Aadi Bioscience 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
生物技术 行业的其他推荐联系人
消息
Foghorn Therapeutics 的最新新闻稿
- Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences | Foghorn Therapeutics
- Foghorn Therapeutics Announces Upcoming Investor Conference Participation | Foghorn Therapeutics
- Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS | Foghorn Therapeutics
- Foghorn Therapeutics Provides First Quarter 2022 Corporate Update | Foghorn Therapeutics
- Foghorn Therapeutics Presents New Preclinical Data on Novel BRG1/BRM Inhibitor FHD-286 at the 2022 AACR Annual Meeting | Foghorn Therapeutics
- Foghorn Therapeutics to Present Preclinical Data For FHD-286 at the 2022 AACR Annual Meeting | Foghorn Therapeutics
- Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day | Foghorn Therapeutics
- Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook | Foghorn Therapeutics
- Foghorn Therapeutics to Participate at the Cowen’s 42nd Annual Health Care Conference | Foghorn Therapeutics
- News | Foghorn Therapeutics
- View more press releases Close
通过电子邮件
